[First clinical experiences with the small molecular synthetic thrombin inhibitor 4-amidinophenylpyruvic acid (APPA)].
D000328:Adult; D000368:Aged; D000578:Amidines / Q000627:therapeutic use; D000798:Angiomatosis / Q000150:complications; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006505:Hepatitis / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D010667:Phenylpyruvic Acids / Q000627:therapeutic use*; D011086:Polycythemia / Q000150:complications; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000578:Amidines; D010667:Phenylpyruvic Acids; D005340:Fibrinogen; D013917:Thrombin
Erste klinische Erfahrungen mit dem kleinmolekularen synthetischen Thrombininhibitor 4-Amidinophenylbrenztraubensäure (APPA).